The results from Pons-Tostivint et al. [11] demonstrated that, when compared to patients who did not undergo local regional treatment (LRT), LRT significantly improved OS in HR+/HER2- breast cancer patients (61.6 vs. 45.9 months; p < 0.001) as well as in HER2+ cases (77.2 vs. 52.6 months; p = 0.008). The gene discussed is ERBB2; the disease is breast cancer.